PharmaCorp Rx EV/EBITDA

EV/EBITDA (Enterprise Value to EBITDA) of PharmaCorp Rx is -50.04 in 2026.

EV/EBITDA (Enterprise Value to EBITDA) of PharmaCorp Rx changed from -129.19 to -50.04, representing a -61.26% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/EBITDA (Enterprise Value to EBITDA) PharmaCorp Rx since 2006 – with annual values, charts, and detailed analysis.

The EV/EBITDA ratio is a widely used valuation metric that compares a company's enterprise value to its EBITDA. It normalizes for differences in capital structure, taxation, and depreciation policies.

To evaluate EV/EBITDA (Enterprise Value to EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBITDA (Enterprise Value to EBITDA).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBITDA (Enterprise Value to EBITDA)'s PharmaCorp Rx with sector peers and the industry average to assess whether it is attractive.